LIGAND PHARMACEUTICALS (LGND)
US53220K5048 - Common Stock
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Ligand to Present at Stifel 2024 Healthcare Conference
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Notable Tuesday Option Activity: LGND, ABNB, RMBS
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs
See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
Top Buys by Directors: Davis's $243.5K Bet on LGND
Top Buys by Top Brass: Chief Executive Officer Davis's $243.5K Bet on LGND
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down.
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ligand Pharmaceuticals (NASDAQ:LGND) just reported results for the second quart...
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Ligand Reports Second Quarter 2024 Financial Results
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
See How Ligand Pharmaceuticals Ranks Among Analysts' Top Picks With Strong Buyback Activity
Ligand to Acquire APEIRON Biologics AG for $100 Million
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board
Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
Ligand to Participate in Upcoming Investor Conferences
3 Magnificent Growth Stocks to Buy Hand Over Fist
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off
With the innovation space possibly getting overstretched, these biotech stocks to buy could benefit from a sector rotation.
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ligand Pharmaceuticals (NASDAQ:LGND) just reported results for the first quarte...
Ligand Reports First Quarter 2024 Financial Results
